Kenneth Getz, MBA

Limited evidence surrounds direct-to-patient clinical trial site models, despite growing literature showing that decentralized approaches can improve patient access, enrollment performance, and operational efficiency while reducing participant burden.

The execution translation gap—the failure to convert identified problems into coordinated, timely action—costs millions per trial through delayed amendments, persistent deviations, and slow site activation, yet remains addressable through aligned accountability and proactive execution management.

Analysis from the Tufts Center for the Study of Drug Development suggests that transparency in clinical evidence, community engagement, and more representative clinical trials are key factors associated with faster vaccine adoption and improved public trust.

First-of-its-kind consortium dedicated to accelerating new medicines development through optimizing patient advocacy group—industry collaboration.

Study uncovers realistic goals in efforts to embrace decentralized clinical trials.

Study by Tufts CSDD uncovers potential reasons behind CRA shortages, turnover, experience requirements, and more.

2020 Tufts CSDD study examines relationship between investigative site personnel diversity and study participant diversity.

Study uncovers pre-pandemic deviation levels.

Reminding clinical research stakeholders to reprioritize routine assessment of patient satisfaction as a primary outcome measure in patient-centric activities.

New benchmarks uncover a maturing and globally-shifting market.

Improving receptivity and response to the evolving nature of clinical trial patient oversight.

Compression between phases to accelerate cycle time.

Battle for trust ensues as vaccines are set for approval.

Comparing late-stage COVID-19 vaccine trials to historical practices.

Record numbers point to new R&D operating environment, driven by a changing community of sponsors.

Tracking the evolution and effectiveness of CISCRP’s clinical research awareness and literacy campaigns.

It’s time to establish standard practices to return clinical trial results summaries to patients.

To inform our understanding of public and patient trust and confidence, this article provides a high-level summary of the results of two studies monitoring trends in international public and patient attitudes and perceptions.

Reexamining traditional cycle-time reduction strategies is critical for sponsors, CROs, and sites.

Sobering statistics collected on clinical trial execution point to the eventual convergence of healthcare and clinical research operating environments.